✦ LIBER ✦

A randomized, double-blind, placebo-controlled, phase I study of MEDI-545, an anti–interferon-alfa monoclonal antibody, in subjects with chronic psoriasis

✍ Scribed by Robert Bissonnette; Kim Papp; Catherine Maari; Yihong Yao; Gabriel Robbie; Wendy I. White; Chenxiong Le; Barbara White

Book ID: 116585702
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 325 KB
Volume: 62
Category: Article
ISSN: 1097-6787
DOI: 10.1016/j.jaad.2009.05.042

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy and safety of itolizumab, a nov

Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: Results of a double-blind, randomized, placebo-controlled, phase-III study

✍ Krupashankar, D.S.; Dogra, Sunil; Kura, Mahendra; Saraswat, Abir; Budamakuntla, 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 694 KB

LY2439821, a humanized anti–interleukin-

LY2439821, a humanized anti–interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study

✍ M. C. Genovese; F. Van den Bosch; S. A. Roberson; S. Bojin; I. M. Biagini; Peter 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 182 KB 👁 1 views

MTRX1011A, a humanized anti-CD4 monoclon

MTRX1011A, a humanized anti-CD4 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a Phase I randomized, double-blind, placebo-controlled study incorporating pharmacodynamic biomarker assessments

✍ Scheerens, Heleen; Su, Zheng; Irving, Bryan; Townsend, Michael J; Zheng, Yanan; 📂 Article 📅 2011 🏛 BioMed Central 🌐 English ⚖ 260 KB

Phase I, double-blind, randomized, place

Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease

✍ C. Janneke van der Woude; Pieter Stokkers; Ad A. van Bodegraven; Gert Van Assche 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 274 KB 👁 2 views

Background: NI-0401 is a fully human monoclonal antibody, which binds to the CD3 subunit of the T-cell receptor, causing modulation of T-cell activity. We investigated the safety and the ability to modulate the TCR-CD3 complex of NI-0401 in patients with active Crohn's disease (CD). Methods: A doub

A randomized, double-blind, placebo-cont

A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis

✍ Gerald G. Krueger; Kim A. Papp; Dow B. Stough; Keith H. Loven; Wayne P. Gulliver 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 480 KB

A multiple dose randomized double-blind

A multiple dose randomized double-blind placebo-controlled study to determine the efficacy and safety of a humanized anti-CD4 monoclonal antibody in the treatment of moderate to severe chronic psoriasis vulgaris

✍ Gottlieb, AB; Krueger, J; Lebwohl, M; Gisoldi, E; Grossman, RM; Wacholtz, MC 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 190 KB